Malay Mail

Beyfortus (Nirsevimab) now available in Malaysia to help protect all infants against RSV disease

Sanofi and AstraZeneca’s Beyfortus (Nirsevimab) is now approved by the National Pharmaceutical Regulatory Agency (NPRA) and ...
Endocrinology Advisor

FDA Looks Into Reports of Deaths After COVID Vaccination

Federal officials say the FDA is reviewing reports of possible deaths in adults and children following COVID-19 vaccination.
Pulmonology Advisor

FDA Reviewing RSV Drugs for Infants, Though No Safety Issues Found

Federal regulators have begun a safety review of 2 RSV medicines used to protect infants, even though no safety problems have been reported.
Enquirer 360

FDA Reassesses Safety of Infant RSV Treatments

U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.